A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionKatharina A. Mayer, Georg A. Böhmig, Eva Schrezenmeier et al.|New England Journal of Medicine|2024Cited by 151
Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titersHannes Vietzen, Elisabeth Puchhammer-Stöckl, Eva‐Maria Wendel et al.|Nature Communications|2025Cited by 16
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort StudyMatthias Diebold, Georg A. Böhmig, Hannes Vietzen et al.|Transplantation|2024Cited by 13
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.Katharina A. Mayer, Georg A. Böhmig, Eva Schrezenmeier et al.|Transplantation|2024Cited by 0
Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory DiseasesHannes Vietzen, Paulus Rommer, Laura M. Kühner et al.|JAMA Neurology|2026Cited by 0